about
P1889
Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activityBiological, clinical and population relevance of 95 loci for blood lipids[Liver steatosis and in-out of phase MR imaging: theory and clinical applications at 3T]Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy.Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy.Recombinant human plasma phospholipid transfer protein (PLTP) to prevent bacterial growth and to treat sepsis.Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes.The impairment of endothelium-dependent arterial relaxation by 7-ketocholesterol is associated with an early activation of protein kinase CInsulin Dissociates the Effects of Liver X Receptor on Lipogenesis, Endoplasmic Reticulum Stress, and Inflammation.Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.The potential of cholesteryl ester transfer protein as a therapeutic target.LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.Fatty acid metabolism in macrophages: a target in cardio-metabolic diseases.Biological activities of Schottenol and Spinasterol, two natural phytosterols present in argan oil and in cactus pear seed oil, on murine miroglial BV2 cells.Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients.Extreme hyperferritinemia in the setting of acute myeloid leukaemia: a case report of hemophagocytic lymphohistiocytosis.Diagnostic Accuracy of Inflammatory Markers As Early Predictors of Infection After Elective Colorectal Surgery: Results From the IMACORS Study.Are Adiponectin and Leptin Good Predictors of Surgical Infection after Colorectal Surgery? A Prospective Study.Insulin response dysregulation explains abnormal fat storage and increased risk of diabetes mellitus type 2 in Cohen Syndrome.The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis.Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes.The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation.Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice.Prevention of LDL alpha-tocopherol consumption, cholesterol oxidation, and vascular endothelium dysfunction by polyphenolic compounds from red wine.Expression of simian CETP in normolipidemic Fisher rats has a profound effect on large sized apoE-containing HDL.Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short-term hypothyroidism Lack of relationship to lipoprotein abnormalities.Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse.Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity.Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice.Effect of cholesteryl ester transfer protein (CETP) expression on diet-induced hyperlipidemias in transgenic rats.Development of abdominal aortic aneurysm is decreased in mice with plasma phospholipid transfer protein deficiency.Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice.[Raising HDL-cholesterol: the future drug therapy for atherosclerosis?].
P50
Q24290207-FC718816-6D7E-45DD-B7D0-C090DFAEBC64Q24622541-538EE308-5394-4D49-9BE2-F35EC74E53E2Q31144797-25953586-6B18-4E38-9B5D-82BFA3825397Q33394148-F77B954C-583A-4DFB-A3BB-37FA64354B00Q33413130-9E5FD627-B9E1-4DBC-94B5-F06212BDD508Q33780365-B548EF53-CA72-4F31-AEC6-1A3C750E5951Q33926011-75140EDA-4058-4EC1-9779-F334B58EE9C5Q34053107-BB1C3437-45D4-41ED-9301-EB58CB893938Q34221038-D567AA89-2B7C-4ECB-941D-9E0CBDE01D50Q34356216-674AB35D-7ADD-442D-8A31-9890797EAA7AQ34489752-31A56C06-6F9B-43FD-9CFF-9481B910DB70Q35044693-46E538F2-16B4-486F-9C60-20ACB995F1C4Q36466124-FC830AEB-5B7A-4279-A3E8-93964B5D93D8Q37299858-166CAA36-19C2-4FEB-9D75-89E9F30EA61CQ37439803-73C32AEB-C936-4634-B969-3D620FE126AFQ38554684-A1DF4021-5FE0-4BBC-8A49-CF6080706AD9Q38739920-00A085EA-D305-4C24-888D-59CA59D5B14EQ39015453-DC573D45-0F79-4214-B820-CCB254008E5BQ39019871-750CA8BB-4B00-443F-AF07-055A1A9CF6FFQ39758886-A2C133DE-2CD0-4824-889D-18FE9F209A57Q40099593-12B0DEE5-9D6E-4FB6-89DD-5617B5B4963AQ41127674-0F1B72B9-DCA9-4ADC-9A4F-65DA573E16F4Q41137949-26BB8A9D-3BD2-4F49-B051-2A93BBA11B69Q41376626-E1F2AFC7-B8FF-4ADF-9618-A7DC7D6AFAD4Q41867827-878FA0DE-906F-4E07-AAAE-565D18B7FC06Q42913239-1D8F4314-5A82-4D6E-AFF7-01E0CF41A6D2Q42923866-7B7524E5-8EBF-4AE1-851F-AFED90A393B8Q43647722-77904F1A-543C-480D-81AE-3E43FACE2E88Q44031811-8FFF701A-80AA-47DB-8729-999990C964D9Q44123466-217CFECB-11C2-4C9E-9079-1D1CBA0F0893Q44231232-A7D1B858-2087-4AB0-AFDA-396C5FE96F9FQ44406153-F18DE0EB-67F9-4694-BB7E-70931BC8A1A4Q44695918-A94B979E-845F-4B68-8023-EBA5C5234658Q45014717-D11C974D-E589-4D3C-824A-01274C4FE9BDQ45077951-E9CCE1AF-6DCB-4361-80C7-6D22359DEDC1Q45171520-5EF05B72-E823-48F9-A084-C9112D29920BQ45253382-E815CB11-391D-4CB7-9692-D62292A59A2AQ46199546-8E3DCED4-CEA8-4829-ADF2-8840C5EDA4F3Q46623064-05177B05-298F-44D8-8AD8-34D5068CB2DEQ46649886-4C8473D0-CC8A-4398-B593-D58C9970D3C5
P50
description
medical researcher
@en
onderzoeker
@nl
հետազոտող
@hy
name
David Masson
@ast
David Masson
@en
David Masson
@es
David Masson
@nl
type
label
David Masson
@ast
David Masson
@en
David Masson
@es
David Masson
@nl
prefLabel
David Masson
@ast
David Masson
@en
David Masson
@es
David Masson
@nl
P1053
R-4557-2017
P106
P1889
P21
P31
P3829
P496
0000-0003-1692-0699